Companies formed

Since 1987, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and in recent years has spun out 15-20 new companies every year.

Over £2.5bn in external investment has been raised by Oxford University Innovation spinouts since 2010, and ten of our current portfolio are currently listed in London and New York.

The creation of new spinout companies, most of which are listed below, also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.

Expertise and knowledge regarding data privacy, ethics, data security and public policy in connection with technology use.

Incorporated in August 2020

Origin: Oxford University, The Oxford Internet Institute

Development of asthma monitoring system

Incorporated in November 2017

Origin: Oxford University, Department of Engineering Science

A proprietary multi-omics discovery platform to resolve RNA-centric mechanisms in rare and chronic diseases.

Incorporated in December 2022

Origin: Oxford University, NDORMS

Advanced materials and technologies in safe, lightweight, high performance hydrogen storage technology.

Incorporated in January 2011

Origin: Oxford University, Science and Technology Facilities Council

Celleron is an oncology healthcare company that has developed biomarkers using epigenetic techniques that match drugs to responsive disease.

Incorporated in November 2005

Origin: Oxford University, Sir William Dunn School of Pharmacology

Circadian Therapeutics identify and bring to market pharmaceutical and diagnostic platforms for the effective management of physiological and pathological conditions through their ability to modify the body's circadian rhythms.

Incorporated in September 2016

Origin: Oxford University, Ophthalmology

ClinOx offers clients knowledge and expertise in the development, placement, conduct and analysis of early phase oncology clinical trials, with particular emphasis on pharmacokinetic and mechanistic endpoints.

Incorporated in June 2007

Origin: Oxford University, Nuffield Division of Clinical and Laboratory Sciences

Using leading edge human biomimetic platforms to test and develop therapeutics for serious human diseases.

Incorporated in July 2009

Origin: Oxford University, Institute of Biomedical Engineering

Cocotec builds software tools, which harness the power of automated formal verification. Its product, the Coco Platform, comes with a powerful software development environment that enables developers to build their software, automatically verify whether it is correct, and then generate high quality reliable code.

Incorporated in November 2018

Origin: Oxford University, Department of Computer Science

Digital CBTe software.

Incorporated in December 2022

Origin: Oxford University, Department of Psychiatry

Crysalin develop a protein lattice technology that is founded on a novel form of highly ordered materials, crysalins, that are produced through modification of naturally occurring protein building blocks.

Incorporated in June 2007

Origin: Oxford University, Department of Biochemistry

Cytox develops a technology platform for tests to identify individuals at risk of cognitive decline, Alzheimer’s disease and other dementias.

Incorporated in October 2006

Origin: Oxford University, Nuffield Department of Clinical Neurosciences

Research and experimental development on biotechnology.

Incorporated in July 2020

Origin: Oxford University, Oncology

Sparks Background Image

Ready to get in touch?

Contact Us
Sparks Background Image
© Oxford University Innovation